Oncolytic parvoviruses: from basic virology to clinical applications
- PDF / 1,041,128 Bytes
- 33 Pages / 595 x 842 pts (A4) Page_size
- 45 Downloads / 180 Views
Oncolytic parvoviruses: from basic virology to clinical applications Virology Journal (2015):6Sample doi:10.1186/s12985-014-0223-y Antonio Marchini ([email protected]) Serena Bonifati ([email protected]) Eleanor M Scott ([email protected]) Assia L Angelova ([email protected]) Jean Rommelaere ([email protected]) Sample
ISSN Article type
1743-422X Review
Submission date
4 August 2014
Acceptance date
3 December 2014
Article URL
http://dx.doi.org/10.1186/s12985-014-0223-y
Like all articles in BMC journals, this peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see copyright notice below). Articles in BMC journals are listed in PubMed and archived at PubMed Central. For information about publishing your research in BMC journals or any BioMed Central journal, go to http://www.biomedcentral.com/info/authors/
© 2015 Marchini et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Oncolytic parvoviruses: from basic virology to clinical applications Antonio Marchini1 Email: [email protected] Serena Bonifati1 Email: [email protected] Eleanor M Scott1 Email: [email protected] Assia L Angelova1 Email: [email protected] Jean Rommelaere1* * Corresponding author Email: [email protected] 1
Infection and Cancer Program, Tumor Virology Division (F010), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
Abstract Accumulated evidence gathered over recent decades demonstrated that some members of the Parvoviridae family, in particular the rodent protoparvoviruses H-1PV, the minute virus of mice and LuIII have natural anticancer activity while being nonpathogenic to humans. These studies have laid the foundations for the launch of a first phase I/IIa clinical trial, in which the rat H-1parvovirus is presently undergoing evaluation for its safety and first signs of efficacy in patients with glioblastoma multiforme. After a brief overview of the biology of parvoviruses, this review focuses on the studies which unraveled the antineoplastic properties of these agents and supported their clinical use as anticancer therapeutics. Furthermore, the development of novel parvovirus-based anticancer strategies with enhanced specificity and efficacy is discussed, in particular the development of second and third generation vectors and the combination of parvoviruses with other anticancer agents. Lastly, we address the key challenges that remain towards a more rational and efficient use of oncolytic parvoviruses in clinical settings, and discuss how a better understanding of the virus life-cycle and of the cellular factors involve
Data Loading...
